SCHLAP1 and prostate carcinoma: For instance, John et al. tested the expression of lnc-SChLAP1 in 1,008 prostate cancer tissues, found that it was notably upregulated, and further identified high SChLAP1 expression as significantly prognostic for metastatic disease progression (Prensner et al., 2014).